The U.S. House of Representatives is poised to consider a bill that has already passed the Senate and aims to streamline patent litigation for biologic drugs. This legislation focuses on reducing the number of patents that manufacturers of biologic drugs can assert against biosimilars. The goal is to simplify the pathway to market for biosimilars, which could result in lower drug prices.
This development is part of a broader effort to address high drug costs and promote competition in the pharmaceutical industry. As the bill moves through the House, it will be closely watched by both advocates for reduced drug prices and stakeholders in the biotech sector. Further details on the legislative process and implications can be found in the original Law360 article.